人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值

刘洋; 胡奕炀; 刘月平; 牛淑瑶; 丁平安; 田园; 郭洪海; 杨沛刚; 张泽; 郑涛; 檀碧波; 范立侨; 李勇; 赵群

doi:10.19401/j.cnki.1007-3639.2023.04.008

您当前的位置：

首页 >

文章列表页 >

人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值

论著 | 更新时间：2025-12-31

- 人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值
- The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
- 中国癌症杂志 2023年33卷第4期页码：377-387
- 作者机构：
  
  1. 河北医科大学第四医院外三科，河北石家庄 050011
  2. 河北医科大学第四医院病理科，河北石家庄 050011
- 作者简介：
  
  [ "刘洋（ORCID：0000-0002-0339-0935），硕士，主治医师。" ]
  赵群（ORCID：0000-0003-1603-3002），博士，教授、主任医师，河北医科大学第四医院副院长。
- 基金信息：
  
  政府资助临床医学优秀人才培养项目(2019139);河北省胃癌精准诊断与综合治疗重点实验室项目(SZX2022014)
- DOI：10.19401/j.cnki.1007-3639.2023.04.008
  中图分类号： R735.2
- 收稿：2022-05-27，
  
  修回：2023-03-13，
  
  纸质出版：2023-04-30
- 稿件说明：
移动端阅览
刘洋, 胡奕炀, 刘月平, 等. 人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值[J]. 中国癌症杂志, 2023,33(4):377-387.

Yang LIU, Yiyang HU, Yueping LIU, et al. The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy[J]. China Oncology, 2023, 33(4): 377-387.
刘洋, 胡奕炀, 刘月平, 等. 人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值[J]. 中国癌症杂志, 2023,33(4):377-387. DOI： 10.19401/j.cnki.1007-3639.2023.04.008.

Yang LIU, Yiyang HU, Yueping LIU, et al. The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy[J]. China Oncology, 2023, 33(4): 377-387. DOI： 10.19401/j.cnki.1007-3639.2023.04.008.

摘要

背景与目的：

胃癌存在较高的肿瘤异质性，部分胃癌患者新辅助化疗（neoadjuvant chemotherapy，NAC）前后人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）表达明显差异化。为了进一步研究HER2表达的异质性，并减少人为评估的视觉误差，本研究采用人工智能（artificial intelligence，AI）辅助显微镜对胃癌患者NAC前后HER2表达进行评估，评价AI的实用性及可行性，并研究NAC对胃癌患者HER2表达的影响，为后续治疗提供参考。

方法：

收集来自以河北医科大学第四医院为主的多中心、前瞻性、随机对照Ⅲ期临床试验（NCT01516944）中接受NAC的397例胃癌患者临床资料，NAC前胃镜咬检及NAC后手术标本HER2分别采用传统视觉评估及AI辅助显微镜评估，并设定3名高年资病理科医师综合评估结果为金标准。分析两种评估结果与金标准的一致性，探讨影响NAC前后HER2表达变化的临床病理学特征及表达改变对患者预后的影响。

结果：

相较于视觉评估，AI评估结果与金标准的一致性更佳（0.766

0.853，0.773

0.876）。通过AI评估，97例（24.43%）患者的HER2在NAC后出现表达下调，而27例（6.80%）患者出现HER2表达上调。单因素分析显示HER2表达改变与淋巴结转移（ypN）（

= 0.019）、肿瘤退缩分级（

= 0.003）明显相关。肿瘤退缩不佳是影响HER2表达上调的独立危险因素（

= 0.032）。预后方面，病理学完全缓解（pathologic complete response，pCR）患者5年总生存（overall survival，OS）率、无病生存（disease-free survival，DFS）率均明显优于非pCR患者（92.9%

42.5%，

= 0.002；92.9%

36.0%，

= 0.001）。而在非pCR患者中，NAC后HER2表达下调者5年OS率和DFS率均优于上调者（56.7%

30.5%，

0.001；56.1%

23.0%，

0.001）；且在非pCR的HER2 2 + /3 + 患者中，NAC后HER2表达下调者5年OS率和DFS率均优于HER2表达无改变者（56.7%

33.5%，

= 0.003；56.1%

32.0%，

= 0.002）。

结论：

AI技术应用于胃癌NAC患者HER2评估能减少人为视觉测量误差，可以成为高效、精准评估HER2表达的有力工具。NAC后pCR及HER2表达下调的胃癌患者具有更好的远期生存。若患者HER2表达上调可能提示预后不佳，临床上更应关注此类患者出现复发转移情况，并及时调整治疗方案。

Abstract

Background and purpose:

Tumor heterogeneity exists in gastric cancer. The expression of human epidermal growth factor receptor 2 (HER2) is significantly different in some gastric cancer patients before and af

ter neoadjuvant chemotherapy (NAC). In order to further study the heterogeneity of HER2 expression and reduce the visual error of human interpretation

we used phase Ⅲ artificial intelligence (AI) to assess the HER2 status of gastric cancer patients pre-NAC and post-NAC to evaluate the practicability and feasibility of AI

and studied the effect of NAC on HER2 expression in gastric cancer patients

so as to provide reference for subsequent treatment.

Methods:

Clinical data of 397 gastric cancer patients receiving NAC were collected from a multicenter

prospective

randomized controlled phase Ⅲ clinical trial (NCT01516944) mainly based on on the Fourth Hospital of Hebei Medical University. HER2 expression in samples of pre-NAC endoscopic biopsies and post-NAC surgical specimens was first assessed visually by 2 pathologists using optical microscope followed by AI-assisted microscope respectively. The comprehensive results of three senior pathologists were set as the gold standard. The consistency between the two assessment results and the gold standard was analyzed

and the clinicopathological features affecting the expression changes of HER2 pre- and post-NAC and the effect of HER2 change on prognosis were also explored.

Results:

Compared with visual assessment

the consistency between AI assessment results and gold standard was better (0.766

0.853

0.773

0.876). HER2 expression assessed by AI was down-regulated in 97 patients (24.43%) post-NAC and up-regulated in 27 patients (6.80%). Change of HER2 expression was significantly correlated with lymph node metastasis (ypN

=0.019) and tumor regression grade (

=0.003). Poor tumor regression was an independent risk factor for the upregulation of HER2 (

=0.032). The 5-year overall survival (OS) rate and disease-free survival (DFS) rate of pathologic complete response (pCR) patients were significantly better compared with non-pCR patients (92.9%

42.5%

=0.002; 92.9%

36.0%

=0.001). In non-pCR patients

the 5-year OS and DFS rates of HER2 down-regulated patients post-NAC were better compared with HER2 up-regulated patients(56.7%

30.5%

0.001; 56.1%

23.0%

0.001). And for those HER2 2+/3+ non-pCR patients

the 5-year OS and DFS rates of HER2 down-regulated patients post-NAC were better compared with HER2 unchanged patients (56.7%

33.5%

=0.003; 56.1%

32.0%

=0.002).

Conclusion:

The application of AI technology in HER2 assessment of NAC patients with gastric cancer can reduce visual measurement error

and AI could be a powerful tool to assess HER2 expression efficiently and accurately. Gastric cancer patients with pCR and down-regulated HER2 post-NAC are more likely to achieve better long-term survival. If upregulation of HER2 status may suggest poor prognosis

attention should be paid closely to the recurrence and metastasis of such patients

and the treatment should be adjusted in time.

关键词

Keywords

references

International Agency for Research on Cancer World Health Organization IARC . GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [J ] . Globocan , 2012 , 2012 : 3 - 6 .

STRONG V E , WU A W , SELBY L V , et al . Differences in gastric cancer survival between the US and China [J ] . J Surg Oncol , 2015 , 112 ( 1 ): 31 - 37 . DOI: 10.1002/jso.23940 http://doi.org/10.1002/jso.23940

赵群 , 李勇 , 乔喜 , 等 . 胃癌组织中HER2蛋白的过表达与临床病理的相关分析 [J ] . 肿瘤学杂志 , 2015 , 21 ( 5 ): 360 - 364 .

ZHAO Q , LI Y , QIAO X , et al . Correlation between overexpression of HER2 protein and clinicopathology in gastric cancer [J ] . J Chin Oncol , 2015 , 21 ( 5 ): 360 - 364 .

BANG Y J , VAN CUTSEM E , FEYEREISLOVA A , et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J ] . Lancet , 2010 , 376 ( 9742 ): 687 - 697 . DOI: 10.1016/S0140-6736(10)61121-X http://doi.org/10.1016/S0140-6736(10)61121-X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X

KUROKAWA Y , MATSUURA N , KIMURA Y , et al . Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer [J ] . Gastric Cancer , 2015 , 18 ( 4 ): 691 - 697 . DOI: 10.1007/s10120-014-0430-7 http://doi.org/10.1007/s10120-014-0430-7

YAGI S , WAKATSUKI T , YAMAMOTO N , et al . Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer [J ] . Gastric Cancer , 2019 , 22 ( 3 ): 518 - 525 . DOI: 10.1007/s10120-018-0887-x http://doi.org/10.1007/s10120-018-0887-x

MOTOSHIMA S , YONEMOTO K , KAMEI H , et al . Prognostic implications of HER2 heterogeneity in gastric cancer [J ] . Oncotarget , 2018 , 9 ( 10 ): 9262 - 9272 . DOI: 10.18632/oncotarget.24265 http://doi.org/10.18632/oncotarget.24265

LORDICK F , KANG Y K , CHUNG H C , et al . Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial [J ] . Lancet Oncol , 2013 , 14 ( 6 ): 490 - 499 . DOI: 10.1016/S1470-2045(13)70102-5 http://doi.org/10.1016/S1470-2045(13)70102-5

QAISER T , RAJPOOT N M . Learning where to see: a novel attention model for automated immunohistochemical scoring [J ] . IEEE Trans Med Imaging , 2019 , 38 ( 11 ): 2620 - 2631 . DOI: 10.1109/TMI.42 http://doi.org/10.1109/TMI.42 https://ieeexplore.ieee.org/xpl/RecentIssue.jsp?punumber=42 https://ieeexplore.ieee.org/xpl/RecentIssue.jsp?punumber=42

ZHAO Q , LIAN C H , HUO Z B , et al . The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: a multicenter randomized clinical trial [J ] . Cancer Med , 2020 , 9 ( 16 ): 5731 - 5745 . DOI: 10.1002/cam4.v9.16 http://doi.org/10.1002/cam4.v9.16 https://onlinelibrary.wiley.com/toc/20457634/9/16 https://onlinelibrary.wiley.com/toc/20457634/9/16

ZHANG J , TIAN K , DONG P , et al . Microscope based HER2 scoring system [EB/OL ] . 2020: arXiv: 2009.06816 . https://arxiv.org/abs/2009.06816 https://arxiv.org/abs/2009.06816 https://arxiv.org/abs/2009.06816 [2022-09-01] .

《胃癌HER2检测指南2016版》专家组 . 胃癌HER2检测指南(2016版) [J ] . 中华病理学杂志 , 2016 , 45 ( 8 ): 528 - 532 .

HER2 Detection Guidelines for Gastric Cancer (2016 edition) Expert Group . HER2 detection guidelines for gastric cancer (2016 edition) [J ] . Chin J Pathol , 2016 , 45 ( 8 ): 528 - 532 .

BARTLEY A N , WASHINGTON M K , COLASACCO C , et al . HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology [J ] . J Clin Oncol , 2017 , 35 ( 4 ): 446 - 464 . DOI: 10.1200/JCO.2016.69.4836 http://doi.org/10.1200/JCO.2016.69.4836

JI J , SHEN L , LI Z , et al . Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: a randomized phase Ⅲ trial (RESOLVE trial) [J ] . Ann Oncol , 2019 , 30 : v877 .

殷科 , 曹永晋 . 曲妥珠单抗新辅助化疗表皮生长因子受体2阳性乳腺癌的临床疗效及安全性评价 [J ] . 中国临床药理学杂志 , 2015 , 31 ( 9 ): 725 - 728 .

YIN K , CAO Y J . Study on efficacy and safety of trastuzumab chemotherapy for the treatment of human epidermal growth factor receptor-2 positive breast cancer [J ] . Chin J Clin Pharmocol , 2015 , 31 ( 9 ): 725 - 728 .

CHUA C , TAN I B , YAMADA Y , et al . Phase Ⅱ study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer [J ] . Cancer Chemother Pharmacol , 2015 , 76 ( 2 ): 397 - 408 . DOI : 10.1007/s00280-015-2811-y http://doi.org/10.1007/s00280-015-2811-y http://link.springer.com/10.1007/s00280-015-2811-y http://link.springer.com/10.1007/s00280-015-2811-y

RYU M H , YOO C , KIM J G , et al . Multicenter phase Ⅱ study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer [J ] . Eur J Cancer , 2015 , 51 ( 4 ): 482 - 488 . DOI: 10.1016/j.ejca.2014.12.015 http://doi.org/10.1016/j.ejca.2014.12.015 https://linkinghub.elsevier.com/retrieve/pii/S0959804915000040 https://linkinghub.elsevier.com/retrieve/pii/S0959804915000040

HE Q F , CHEN J H , ZHOU K , et al . Effect of additional trastuzumab in neoadjuvant and adjuvant treatment for patients with resectable HER2-positive gastric cancer [J ] . Ann Surg Oncol , 2021 , 28 ( 8 ): 4413 - 4422 . DOI: 10.1245/s10434-020-09405-6 http://doi.org/10.1245/s10434-020-09405-6

YUE M , ZHANG J , WANG X R , et al . Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study [J ] . Virchows Arch , 2021 , 479 ( 3 ): 443 - 449 . DOI: 10.1007/s00428-021-03154-x http://doi.org/10.1007/s00428-021-03154-x

TUOMINEN V J , TOLONEN T T , ISOLA J . ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry [J ] . Histopathology , 2012 , 60 ( 5 ): 758 - 767 . DOI: 10.1111/j.1365-2559.2011.04142.x http://doi.org/10.1111/j.1365-2559.2011.04142.x

HELIN H O , TUOMINEN V J , YLINEN O , et al . Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry [J ] . Virchows Arch , 2016 , 468 ( 2 ): 191 - 198 . DOI: 10.1007/s00428-015-1868-7 http://doi.org/10.1007/s00428-015-1868-7 http://link.springer.com/10.1007/s00428-015-1868-7 http://link.springer.com/10.1007/s00428-015-1868-7

HEDNER C , BORG D , NODIN B , et al . Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment [J ] . J Clin Pathol , 2018 , 71 ( 5 ): 451 - 462 . DOI: 10.1136/jclinpath-2017-204774 http://doi.org/10.1136/jclinpath-2017-204774

WATSON S , VALIDIRE P , CERVERA P , et al . Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study [J ] . Ann Oncol , 2013 , 24 ( 12 ): 3035 - 3039 . DOI: 10.1093/annonc/mdt393 http://doi.org/10.1093/annonc/mdt393

JORDAN N V , BARDIA A , WITTNER B S , et al . HER2 expression identifies dynamic functional states within circulating breast cancer cells [J ] . Nature , 2016 , 537 ( 7618 ): 102 - 106 . DOI: 10.1038/nature19328 http://doi.org/10.1038/nature19328

PUSZTAI L , VIALE G , KELLY C M , et al . Estrogen and HER2 receptor discordance between primary breast cancer and metastasis [J ] . Oncol , 2010 , 15 ( 11 ): 1164 - 1168 . DOI: 10.1634/theoncologist.2010-0059 http://doi.org/10.1634/theoncologist.2010-0059 https://academic.oup.com/oncolo/article/15/11/1164/6399745 https://academic.oup.com/oncolo/article/15/11/1164/6399745

WETZEL C L , SUTTON T L , GARDINER S , et al . Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes [J ] . J Surg Oncol , 2021 , 124 ( 8 ): 1224 - 1234 . DOI: 10.1002/jso.26646 http://doi.org/10.1002/jso.26646

SEO S , RYU M H , PARK Y S , et al . Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) [J ] . Gastric Cancer , 2019 , 22 ( 3 ): 527 - 535 . DOI: 10.1007/s10120-018-0891-1 http://doi.org/10.1007/s10120-018-0891-1

于观贞 , 魏培莲 , 陈颖 , 等 . 人工智能在肿瘤病理诊断和评估中的应用与思考 [J ] . 第二军医大学学报 , 2017 , 38 ( 11 ): 1349 - 1354 .

YU G Z , WEI P L , CHEN Y , et al . Artificial intelligence in pathological diagnosis and assessment of human solid tumor: application and thinking [J ] . Acad J Second Mil Med Univ , 2017 , 38 ( 11 ): 1349 - 1354 .

浏览量

1916

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

人工智能在胃癌诊疗和患者预后预测中的应用现状及未来展望

胃癌伴神经内分泌肿瘤与单纯型胃癌的免疫微环境特征比较研究

口服营养补充对胃癌根治术后存在营养风险的老年出院患者影响的前瞻性研究

胃癌领域抗肿瘤药物相关间质性肺病/肺炎的研究进展及展望

MRI预测乳腺癌淋巴结状态的研究进展及展望